# US 2003/0215402 A1 · Porphyromonas gingivalis recombinant proteins and truncations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215402 A1
- Document ID: US20030215402A1
- Status: Published application
- Kind: A1
- Application number: 10/283,024
- Filed: 2002-10-28
- Published: 2003-11-20
- Earliest claimed: 2000-04-28
- Assignees: CSL Limited
- Inventors: Ian George Barr; Larissa Czajkowski; Bruce Carter Ross
- Web page: https://patentgrep.com/patent/US20030215402A1

## CPC

- C07K 16/1203: Gram-negative bacteria
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/195: from bacteria
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- Y10S 530/806: Antigenic peptides or proteins
- Y10S 530/825: Bacteria
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to soluble P. gingivalis polypeptides derived from PG32 and PG33 and to polynucleotides encoding these polypeptides. The P. gingivalis polypeptides and nucleotides can be used in compositions for use in raising an immune response in a subject against P. gingivalis and treating or preventing or reducing the severity of the condition known as periodontitis or in other conditions related to infection with P. gingivalis.

## Claims

### Claim 1

A soluble polypeptide, the polypeptide comprising a fragment of the sequence as shown in SEQ ID NO:3 or SEQ ID NO:4.

### Claim 2 (depends on 1)

A soluble polypeptide as claimed in claim 1 wherein the fragment is derived from the region defined by residues 190 to 391 of SEQ ID NO:3 or the region defined by residues 210 to 380 of SEQ ID NO:4.

### Claim 3

A soluble polypeptide of the formula X-Y-Z, wherein
Y is a soluble P. gingivalis fragment consisting of an amino acid sequence selected from the group consisting of residues 86 to 223 of SEQ ID NO:3, residues 191 to 322 of SEQ ID NO:3, residues 193 to 310 of SEQ ID NO:4, residues 191 to 306 of SEQ ID NO:3, residues 224 to 391 of SEQ ID NO:3, residues 213 to 380 of SEQ ID NO:4, residues 286 to 380 of SEQ ID NO:4, residues 224 to 306 of SEQ ID NO:3, residues 213 to 285 of SEQ ID NO:4, residues 281 to 384 of SEQ ID NO:3 and residues 306 to 372 of SEQ ID NO:4; and
X and Z are optional and consist of amino acids or peptides which do not substantially adversely affect the solubility of the P. gingivalis fragment.

### Claim 4 (depends on 3)

A soluble polypeptide as claimed in claim 3 wherein Y is a P. gingivalis fragment consisting of residues 224 to 391 of SEQ ID NO:3 or residues 213 to 380 of SEQ ID NO:4.

### Claim 5 (depends on 3, 4)

A soluble polypeptide as claimed in claim 3 or claim 4 wherein X and/or Z are absent.

### Claim 6

A soluble P. gingivalis polypeptide consisting essentially of a polypeptide having a sequence selected from the group consisting of residues 86 to 223 of SEQ ID NO:3, residues 191 to 322 of SEQ ID NO:3, residues 193 to 310 of SEQ ID NO:4, residues 191 to 306 of SEQ ID NO:3, residues 224 to 391 of SEQ ID NO:3, residues 213 to 380 of SEQ ID NO:4, residues 286 to 380 of SEQ ID NO:4, residues 224 to 306 of SEQ ID NO:3, residues 213 to 285 of SEQ ID NO:4, residues 281 to −384 of SEQ ID NO:3 and residues 306 to 372 of SEQ ID NO:4.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A chimeric or fusion construct comprising a soluble polypeptide as claimed in any one of claims 1 to 6.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

An isolated DNA molecule, the DNA molecule comprising a nucleotide sequence which encodes a soluble polypeptide as claimed in any one of claims 1 to 6.

### Claim 9 (depends on 8)

A recombinant expression vector comprising the DNA molecule of claim 8 operably linked to a transcription regulatory element.

### Claim 10 (depends on 9)

A cell comprising a recombinant expression vector of claim 9.

### Claim 11 (depends on 10)

A method for producing a P. gingivalis polypeptide comprising culturing a cell of claim 10 under conditions that permit expression of the polypeptide.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 8)

A composition for use in raising an immune response directed against P. gingivalis in a subject, the composition comprising an effective amount of at least one soluble polypeptide of any one of claims 1 to 6 and/or at least one DNA molecule of claim 8, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

A composition as claimed in claim 12 wherein the pharmaceutically acceptable carrier is an adjuvant.

### Claim 14 (depends on 12, 13)

A method of reducing or preventing the incidence or severity of P. gingivalis infection in a subject comprising administering to the subject a composition of claim 12 or claim 13.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7)

An antibody raised against a soluble polypeptide of any one of claims 1 to 7.

### Claim 16 (depends on 15)

A composition comprising an antibody of claim 15 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 15)

A method for the treatment or prevention of P. gingivalis infection in a subject comprising passive vaccination of the subject with an antibody of claim 15.

### Claim 18 (depends on 15)

A diagnostic method for detecting the presence or absence of a P. ingivalis polypeptide in a sample, the method comprising contacting the sample with an antibody of claim 15 under conditions sufficient for the antibody to form an immune complex with a P. gingivalis polypeptide in the sample, and detecting the presence or absence of an immune complex.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7)

A diagnostic method for detecting the presence or absence of a P. ingivalis antibody in a sample, the method comprising contacting the sample with a soluble polypeptide of any one of claims 1 to 7 under conditions sufficient for the soluble fragment of polypeptide to form an immune complex with an antibody in the sample, and detecting the presence or absence of an immune complex.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 15)

A kit comprising a soluble polypeptide of any one of claims 1 to 7 and/or an antibody of claim 15.
